RVMD
Revolution Medicines IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$19.17B
P/E Ratio
—
EPS
$-5.95
Beta
1.01
52W High
$124.49
52W Low
$33.25
50-Day MA
$98.65
200-Day MA
$67.32
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Revolution Medicines Inc
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Fundamentals
| Revenue (TTM) | 742,000 |
| Gross Profit (TTM) | $-987.33M |
| EBITDA | $-1.17B |
| Operating Margin | 0.00% |
| Return on Equity | -58.10% |
| Return on Assets | -30.10% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $8.28 |
| Price-to-Book | 12.04 |
| Price-to-Sales (TTM) | 9035.10 |
| EV/Revenue | 8370.02 |
| EV/EBITDA | -9.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -95.20% |
| Shares Outstanding | $198.17M |
| Float | $178.74M |
| % Insiders | 1.93% |
| % Institutions | 102.12% |
Analyst Ratings
Consensus ($133.70 target)
4
Strong Buy16
BuyData last updated: 4/9/2026